Padsevonil
Phase 1Completed 0 watching 0 views this week๐ค Quiet
30
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Elderly Study Participants
Conditions
Elderly Study Participants, Adult Study Participants
Trial Timeline
Jul 9, 2019 โ Oct 3, 2019
NCT ID
NCT04013191About Padsevonil
Padsevonil is a phase 1 stage product being developed by UCB for Elderly Study Participants. The current trial status is completed. This product is registered under clinical trial identifier NCT04013191. Target conditions include Elderly Study Participants, Adult Study Participants.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04136444 | Phase 1 | Terminated |
| NCT04075409 | Phase 1 | Completed |
| NCT04013191 | Phase 1 | Completed |
| NCT03370120 | Phase 2 | Terminated |
| NCT03373383 | Phase 2 | Completed |
Competing Products
15 competing products in Elderly Study Participants
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM150 + Placebo | Astellas Pharma | Phase 1 | 33 |
| ASP3325 + Placebo | Astellas Pharma | Phase 1 | 33 |
| E2022 Tape Formulation | Eisai | Phase 1 | 33 |
| Donepezil | Eisai | Approved | 85 |
| AZD3293 + Placebo | AstraZeneca | Phase 1 | 33 |
| TC-5214 + Placebo | AstraZeneca | Phase 1 | 33 |
| AZD3293 + Placebo | AstraZeneca | Phase 1 | 33 |
| Esmirtazapine | Merck | Phase 3 | 77 |
| Pertuzumab + trastuzumab + Pertuzumab + trastuzumab + metronomic chemotherapy | Roche | Phase 2 | 52 |
| PF-06648671 + Midazolam + Placebo | Pfizer | Phase 1 | 32 |
| PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo + PF-06743649 + Placebo | Pfizer | Phase 1 | 32 |
| Vitamin D + Sham Exercise + Vitamin D + Exercise | Pfizer | Phase 1 | 32 |
| HSK3486 + HSK3486 + HSK3486 + HSK3486 | Haisco Pharmaceutical Group | Phase 1 | 30 |
| TD-1439 + Placebo | Theravance Biopharma | Phase 1 | 28 |
| TD-0714 + Placebo | Theravance Biopharma | Phase 1 | 28 |